Rettatide
[Tirzepatide]

RX only

IMPORTANT INFORMATION: This guide contains essential information for the handling and use of Rettatide [Tirzepatide]. For Research Use Only.

Safety Information & Contraindications

Contraindications: Use is strictly prohibited if you have any of the following conditions:
  • Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
  • Are pregnant or breastfeeding.
  • Have severe gastrointestinal disorders (e.g., gastroparesis).
  • Are under 18 years of age.
  • Are currently using insulin or other glucose-lowering medication without direct medical supervision.
  • Have severe hepatic (liver), renal (kidney), or pancreatic impairment.
Warnings & Precautions: Consult a healthcare professional before use if you have chronic medical conditions or take prescription medications.

Recommended Dosing & Titration

« Swipe table to see all data ↔ »

Week Dosage Frequency Administration Protocol
Week 1–4 2.5 mg Once weekly Initial titration dose to assess tolerance.
Week 5–8 5 mg Once weekly Dose escalation is contingent upon tolerance.
Week 9+ 7.5–10 mg Once weekly Adjust based on progress and tolerance.

Missed Dose Protocol: Take within 72 hours of the scheduled time. Otherwise, skip the dose and wait for the next scheduled injection.

Materials Required

Rettatide materials kit (vials, syringes, swabs)
  • Tirzepatide lyophilized vial × 1
  • Bacteriostatic Water for Injection (BWFI) (3 mL) × 1
  • 3 mL syringe × 1 (for reconstitution)
  • 1 mL insulin syringe (100 units) × 2 (for injection)
  • Alcohol swabs × 4
WARNING: Use only sterile, single-use syringes. Never reuse or share syringes to prevent cross-contamination.

Dose Volume Conversion (3mL Reconstitution)

Use this table to find the correct volume (mL) to draw based on your vial size and target dose. This table assumes a reconstitution with **3 mL of Bacteriostatic Water**.

« Swipe table to see all data ↔ »

Vial Size (Concentration) Target: 2.5 mg Target: 5 mg Target: 7.5 mg Target: 10 mg Target: 15 mg
10 mg Vial
(3.33 mg/mL)		 0.75 mL 1.50 mL 2.25 mL 3.00 mL (Full) Not Supported
15 mg Vial
(5 mg/mL)		 0.50 mL 1.00 mL 1.50 mL 2.00 mL 3.00 mL (Full)
30 mg Vial
(10 mg/mL)		 0.25 mL 0.50 mL 0.75 mL 1.00 mL 1.50 mL

Reconstitution Protocol (Mixing)

  1. Wash hands and sterilize both vial caps with alcohol swabs.
  2. Draw 3 mL of Bacteriostatic Water using the 3 mL syringe.
  3. Inject the water slowly along the inner vial wall. Do not forcefully squirt the water directly onto the powder.
  4. Do not shake. Gently swirl or roll the vial between your hands until the solution is fully dissolved and clear.
  5. Use the conversion table (Section 4) to determine the correct volume, then withdraw the required dose into the insulin syringe for administration.
CAUTION: DO NOT SHAKE. Vigorous agitation can denature the peptide structure, reducing its efficacy.

Administration Technique

  1. Choose site: Recommended injection sites are the abdomen, thigh, or upper arm.
  2. Sterilize: Clean the skin area with an alcohol swab.
  3. Inject: Perform a subcutaneous (SC) injection at a 45–90° angle.
  4. Rotate: Rotate injection sites weekly to prevent lipodystrophy (abnormal fat distribution).
  5. Dispose: Immediately dispose of used syringes safely in a designated sharps container.

(Most users inject into the abdomen for ease of handling.)

Adverse Reactions & Discontinuation

Common Adverse Reactions (CARs):

These are typically mild and transient, especially during dose titration:

  • Nausea, Vomiting
  • Decreased Appetite
  • Diarrhea or Constipation
  • Indigestion, Bloating, or Stomach Discomfort

Less Common Reactions:

  • Fatigue or Dizziness
  • Injection site reactions (redness, itching, irritation)
  • Belching or “sulphur burps”
Serious Adverse Reactions (SARs): Immediately discontinue use and seek emergency medical attention if you experience:
  • Signs of an allergic reaction (rash, hives, swelling, difficulty breathing).
  • Severe, persistent abdominal pain (symptomatic of pancreatitis).
  • Persistent vomiting or signs of dehydration.
  • Vision changes or signs of hypoglycemia (shaking, sweating, confusion, blurred vision).

Storage Conditions & Stability

Condition Requirement
Unreconstituted (Lyophilized) Vial Store refrigerated at 2–8°C (36–46°F). Do not freeze.
Reconstituted Solution Store refrigerated and use within 28 days.
Bacteriostatic Water Intended for single use only after opening.
Transport Keep below 25°C (77°F), protect from sunlight, and avoid shaking.

Frequently Asked Questions (FAQ)

1. How does Tirzepatide work?

It functions as a dual GIP and GLP-1 receptor agonist. This helps regulate appetite, slow gastric emptying (making you feel full longer), and improve insulin sensitivity.

2. What results can I expect?

Clinical results vary. This medication is intended to be used as a research tool. Efficacy is often linked to consistency and complementary lifestyle habits.

3. Do I need to follow a diet or exercise plan?

Yes. For best results, this protocol should be paired with a balanced, calorie-controlled diet and regular physical activity. This is not a substitute for a healthy lifestyle.

4. Can I take this with intermittent fasting?

Combining this medication with extreme dietary practices (like fasting) may increase the risk of hypoglycemia (low blood sugar) or other side effects. Always follow your healthcare provider’s advice.

5. Can I stop once I reach my goals?

Do not stop or adjust your treatment without medical advice. Your healthcare provider will guide you on if, when, and how to taper safely.

Resources & Registration

Scan for video tutorials & customer registration

QR Code for Rettatide tutorials and registration

Rettatide® Tirzepatide – Electronic Instruction Manual